At a glance
- Originator Otsuka Pharmaceutical
- Class Antiarrhythmics; Piperazines; Quinolones; Small molecules
- Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 13 Dec 1994 Discontinued-Preclinical for Arrhythmias in Japan (Unknown route)